Physician profile
George M Doyle
NPI 1407890387
$897.36
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $243 · 2021: $83.81 · 2022: $50.87.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $300.41 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $201.75 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $74.51 | 2019-2020 | |
| Boston Scientific Corporation | $67.48 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.37 | 2019 | |
| Allergan, INC. | $47.15 | 2019-2020 | |
| Antares Pharma, INC. | $29.94 | 2019 | |
| Pfizer INC. | $28.27 | 2019-2020 | |
| Blue Earth Diagnostics | $27.27 | 2019 | |
| Olympus America INC. | $25.45 | 2020 | |
| Myovant Sciences INC. | $23.93 | 2022 | |
| Janssen Biotech, INC. | $15.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.